Except, that future is the present. A company called Recursion Pharmaceuticals (NASDAQ: RXRX) is doing it. Using its access to 65 petabytes' (65 million gigabytes) worth of biological, chemical, and ...

By now, we all know about Palantir, the one-of-a-kind juggernaut meme stock that can’t be stopped. It’s part sledgehammer, ...

Palantir’s revenue growth accelerated to 48% and its adjusted operating margin stands at 46%. That’s an extraordinary ...

Palantir topped $1 billion in quarterly revenue for the first time. Considering the company's extreme valuation, it may be ...

Palantir’s eccentric CEO has led one of the most controversial companies in Silicon Valley to unprecedented success.

Palantir's valuation may appear excessive, but conventional models fail to capture full scope of its embedded optionality.

But as is the case with all next-big-thing innovations, this optimism isn't universal. Although an overwhelming percentage of ...

Palantir Technologies stock (NASDAQ: PLTR) has had a remarkable run this year, more than doubling since early January to ...

Palantir earnings top $1B in Q2 2025 amid AI boom, fueling stock rally and driving massive revenue growth in U.S. commercial ...

Wedbush analyst Dan Ives raised his price target on Palantir Technologies Inc. (NYSE: PLTR) to $200, citing "hyper growth ...

Detailed price information for Palantir Technologies Inc Cl A (PLTR-Q) from The Globe and Mail including charting and trades.

Palantir's revenue jumped 48% year-over-year to $1 billion, $61 million better than Wall Street was expecting. As a result, earnings per share (EPS) increased to 16 cents per share, 2 cents higher ...